Literature DB >> 17768754

Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.

John C Boik1, Robert A Newman, Robert J Boik.   

Abstract

Cancer drugs are commonly administered in the clinic in the form of mixtures, also called cocktails or combinations. Assessment of synergistic and antagonistic interactions between drugs is therefore an important aspect of cancer research. Numerous methods have been proposed to assess drug interactions, each one based on a null (or additive) model. In this paper, the Loewe additivity index is used as a basis. Parameters of concentration-response curves, used as input to the Loewe equation, are estimated with a nonlinear mixed-effects model. The use of a nonlinear mixed-effects model, in combination with the Loewe index and a procedure to calculate confidence intervals of the index, is referred to as the 'MixLow' method. Simulations of a sham mixture of a drug with itself show that the MixLow method provides parameter estimators that are more precise than those produced by the Median-Effect method, a popular approach that uses log linearization of the concentration-response curves. Coverage of confidence intervals for the interaction index is acceptable for the MixLow method but poor for the Median-Effect method. This is the first comparison report of coverage of confidence intervals for the Loewe interaction index. A mixture of vincristine and topotecan is also analyzed by the MixLow method and the results are compared with those previously published. The MixLow method can be used to quantify drug interactions in any fixed-ratio drug combination study that includes within-group and between-group replicates, and where responses follow a sigmoidal pattern. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17768754     DOI: 10.1002/sim.3005

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  21 in total

1.  ANOVA and the analysis of drug combination experiments.

Authors:  John C Ashton
Journal:  Nat Methods       Date:  2015-12       Impact factor: 28.547

2.  A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies.

Authors:  Violeta G Hennessey; Gary L Rosner; Robert C Bast; Min-Yu Chen
Journal:  Biometrics       Date:  2010-12       Impact factor: 2.571

3.  Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Authors:  Christine M Lovly; Johannes M Heuckmann; Elisa de Stanchina; Heidi Chen; Roman K Thomas; Chris Liang; William Pao
Journal:  Cancer Res       Date:  2011-05-25       Impact factor: 12.701

4.  Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.

Authors:  Andrew C Wood; Kateryna Krytska; Hannah T Ryles; Nicole R Infarinato; Renata Sano; Theodore D Hansel; Lori S Hart; Frederick J King; Timothy R Smith; Edward Ainscow; Kathryn B Grandinetti; Tove Tuntland; Sunkyu Kim; Giordano Caponigro; You Qun He; Shiva Krupa; Nanxin Li; Jennifer L Harris; Yaël P Mossé
Journal:  Clin Cancer Res       Date:  2016-12-16       Impact factor: 12.531

5.  Prophylactic and therapeutic functions of drug combinations against noise-induced hearing loss.

Authors:  Jianxin Bao; Michelle Hungerford; Randi Luxmore; Dalian Ding; Ziyu Qiu; Debin Lei; Aizhen Yang; Ruqiang Liang; Kevin K Ohlemiller
Journal:  Hear Res       Date:  2013-06-18       Impact factor: 3.208

6.  A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway.

Authors:  Han Yan; Bo Zhang; Shao Li; Qianchuan Zhao
Journal:  BMC Syst Biol       Date:  2010-04-25

7.  Current Methods for Quantifying Drug Synergism.

Authors:  Jun Ma; Alison Motsinger-Reif
Journal:  Proteom Bioinform       Date:  2019-07-22

8.  Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Authors:  Paola Rogliani; Maria Gabriella Matera; Francesco Facciolo; Clive Page; Mario Cazzola; Luigino Calzetta
Journal:  Br J Pharmacol       Date:  2020-01-29       Impact factor: 8.739

9.  Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Authors:  Adam X Sang; Marla C McPherson; Geoffrey T Ivison; Xiumei Qu; Joseph Rigdon; Carlos O Esquivel; Sheri M Krams; Olivia M Martinez
Journal:  Am J Transplant       Date:  2019-01-09       Impact factor: 8.086

10.  Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Authors:  Marise R Heerma van Voss; Justin D Brilliant; Farhad Vesuna; Guus M Bol; Elsken van der Wall; Paul J van Diest; Venu Raman
Journal:  Med Oncol       Date:  2017-01-30       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.